Abstract
Patients on CAPD using calcium carbonate (CaC03) as phosphate binder might benefit from low -calcium (Ca) concentration dialysis solutions; however, no data are available for the effects of this regimen on Ca metabolism. We studied 10 patients on stable CAPD regimens with standard dialysis solutions (Ca 7 mg/dL) who were taking CaC03 to control hyperphosphatemia (mean daily doses 4.5±2.4 g). Hypercalcemic episodes had been recorded in 6 patients. Standard dialysis solutions were replaced with solutions containing 5 mg/dL of Ca. Calcium and phosphate peritoneal mass transfer (MT), serum concentrations of total Ca, ionized Ca (Ca++), phosphate, intact PTH, and mid-molecular PTH, were evaluated before and 48 hours after change of dialysate. The switch to low-Ca solutions was accompanied by significant changes in calcium mass transfer (Ca MT) (+9.84±48.22 versus −96.74±48.32 mg/day, p<.001). Ca MT was significantly (p<.05) correlated with the serum/ dialysate Cagradient. There was no difference in phosphate MT. Serum Ca++ significantly (p<.05) decreased from 5.20±0.32 to 4.88±0.36 mg/dL, and intact PTH significantly increased (81.5± 139 versus 112.4± 168 pg/mL, p<.05). It is concluded that dialysis solutions with Ca 5 mg/dL result in a negative peritoneal Ca MT and can be useful to prevent and treat hypercalcemia in CAPD patients taking CaC03 as phosphate binder. A careful monitoring of ionized calcium, PTH, and phosphate is suggested when an extensive and long-term use of this solution is considered.
Get full access to this article
View all access options for this article.